Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules

Author(s):  Fortner Jeff, Salton Jason, Carlson Christie, Wheeler Rich, Cote Brianna, Rao Deepa

Issue:  Sep/Oct 2015 - Volume 19, Number 5
View All Articles in Issue

Page(s):  414-419

Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Page 1
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Page 2
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Page 3
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Page 4
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Page 5
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules Page 6

Download in electronic PDF format for $75

Abstract:  The purpose of this research was to collect, analyze, and compare stability data for levothyroxine (T4) powder in the anhydrous and pentahydrate form when prepared as an aliquot and in capsules. Two different compounding pharmacies, Central Iowa Compounding and Gateway Medical Pharmacy, used different forms of T4 and aliquot formulations, which were studied to determine the beyond-use date at ±5% or ±10% of labeled strength. T4 was extracted from aliquot and capsule formulations and assessed using reverse-phase highperformance liquid chromatography validated to differentiate between the degraded and original forms of T4. The results indicate that T4 1:100 aliquot formulation prepared with silica gel or Avicel as filler are stable for 120 days at ±10% labeled potency, but at ±5% labeled potency, the silica gel and Avicel aliquot formulations are stable for 45 and 30 days, respectively. The silica gel capsules prepared from fresh aliquot were stable for 120 days at ±10% labeled potency and 90 days at ±5% labeled potency, while the Avicel capsules prepared from fresh aliquot were stable for 180 days at both ±10% and ±5% labeled potency. Avicel capsules prepared from old aliquot (120 days) and fresh aliquot (1 day) were also compared for stability. The old aliquot Avicel capsules were stable for 14 days at ±5% labeled potency and 150 days at ±10% labeled potency, while new aliquot Avicel capsules were stable for 180 days at both ±10% and ±5% labeled potency. Based on our data, there can be significant variation in the beyond-use dates assigned to T4 capsules based on the diluents used for aliquots, the final capsule formulations, and the potency standards applied. These results also indicate that pharmacists must exercise caution when using older aliquots and may have to assign shorter beyond-use dates.

Related Keywords: levothyroxine, hypothyroidism, thyroid T4 replacement hormone, anhydrous, pentahydrate, aliquots, capsules, stability, potency standards, storage temperature

Related Categories: EXCIPIENTS, FORMULATIONS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Solid State Stability of Extemporaneously Prepared Levothyroxine Aliquots and Capsules
Fortner Jeff
, Salton Jason, Carlson Christie, Wheeler Rich, Cote Brianna, Rao Deepa
Sep/Oct 2015
Pg. 414-419

Stability of Levothyroxine, Doxycycline, Hydrocortisone, and Pravastatin in Liquid Dosage Forms Stored at Two Temperatures
Nahata Milap C
Sep/Oct 2015
Pg. 428-431

Levothyroxine Sodium 100-mcg Capsules
Allen Loyd V Jr
Nov/Dec 2013
Pg. 505

Hypothyroidism: Optimizing Therapy with Slow-Release Compounded Thyroid Replacement
Milner Martin
Jul/Aug 2005
Pg. 268-273

Bioidentical Thyroid Replacement Therapy in Practice: Delivering a Physiologic T4-T3 Ratio for Improved Patient Outcomes with the Listecki-Snyder Protocol
Snyder Scott
, Listecki Robert E
Sep/Oct 2012
Pg. 376-380

Influence of Temperature on the Thirty-Day Chemical Stability of Extemporaneously Prepared Dexamethasone Paste
Dudley Richard
, McDowell Brean, Mahl Carissa, Sarkar Arindam Basu
May/Jun 2012
Pg. 258-261

Thyroid Potency Calculations
Stack Bob
Jul/Aug 2010
Pg. 306-309

The Basics of Compounding: Compounding Special Capsules
Allen Loyd V Jr
Jul/Aug 1999
Pg. 291-294

Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets
Zaid Abdel Naser
, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'
Jul/Aug 2012
Pg. 342-346

Stability of an Extemporaneously Formulated Levothyroxine Sodium Syrup Compounded from Commercial Tablets
Alexander Kenneth S
, Kothapalli Madhu R, Dollimor David
Jan/Feb 1997
Pg. 60-63

Levothyroxine Sodium 40-micro-g/mL Oral Liquid
Allen Loyd V Jr
May/Jun 2007
Pg. 247

Stability of 4-Aminopyridine and 3,4-Diaminopyridine Oral Capsules
Trissel Lawrence A
, Xu Quanyun A, Zhang Yanping
Mar/Apr 2002
Pg. 155-157

The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions
Svirskis Darren
, Lin Shao-Wei, Brown Helen, Sangaroomthong Annie, Shin Daniel, Wang Ziqi, Xu Hongtao, Dean Rebecca, Vareed Preetika, Jensen Maree, Wu Zimei
Mar/Apr 2018
Pg. 164-171

Mean Kinetic Temperature for Controlled Room Temperature Drug Storage: Official Definitions and Example Calculations
Newton David W
Jul/Aug 2019
Pg. 281-287

Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes
McHenry Adam R
, Wempe Michael F, Rice Peter J
May/Jun 2017
Pg. 251-254

Stability of Fagron's Phytobase Cream Compounded with Various Hormones
Wynn Tom
, Taylor Sarah, Zander Clark
Mar/Apr 2021
Pg. 156-162

Differentiation and Treatment of Hypothyroidism, Functional Hypothyroidism, and Functional Metabolism
Paoletti Jim
Nov/Dec 2008
Pg. 488-497

Differentiation and Treatment of Hypothyroidism, Functional Hypothyroidism, and Functional Metabolism
Paoletti Jim
Jan/Feb 2024
Pg. 34-43

Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2
Ford Gina
, Garcia Lea
Jan/Feb 2001
Pg. 52-54

Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
Jan/Feb 2001
Pg. 9-12

Return to Top